Teva debuts generics of Delzicol and Tarceva in the USA

11 May 2019

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) over the last couple of days announced the launch of two new generic copy drugs in the USA.

First up, Teva said on Friday that it had debuted a generic version of Allergan's (NYSE: ALG) Delzicol (mesalamine) delayed-release capsules, 400mg. Mesalamine delayed-release capsules are an aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients five years of age and older, and for the maintenance of remission of ulcerative colitis in adults.

Teva executive vice president and head of North America Commercial, Brendan O’Grady, said: “Ulcerative colitis is a chronic inflammatory bowel disease and we’re proud to provide another treatment option for patients.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK